Xencor Inc (XNCR) was Initiated by Piper Jaffray to “Overweight”. Piper Jaffray advised their investors in a research report released on Oct 4, 2016.
Xencor Inc opened for trading at $24.47 and hit $24.6825 on the upside on Friday, eventually ending the session at $24.49, with a gain of 0.45% or 0.11 points. The heightened volatility saw the trading volume jump to 3,20,637 shares. Company has a market cap of $1,003 M.
In a different news, on Sep 28, 2016, Edgardo Jr Baracchini (Chief Business Officer) sold 10,000 shares at $25.47 per share price. According to the SEC, on Sep 1, 2016, Bassil I Dahiyat (President and CEO) sold 40,000 shares at $21.80 per share price. On Aug 25, 2016, John J Kuch (Vice President, Finance) sold 25,000 shares at $22.04 per share price, according to the Form-4 filing with the securities and exchange commission.
Xencor Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. The Company uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases cancer and other conditions. The Company’s product pipeline includes three lead XmAb-engineered antibodies which include XmAb5871 XmAb7195 and XmAb5574/MOR208. XmAb5871 is indicated for the treatment of moderate-to-severe rheumatoid arthritis. XmAb7195 is the Company’s wholly owned program being developed for the treatment of severe asthma and allergic diseases. XmAb5574/MOR208 is being developed for the treatment of blood-based cancers.